Santé	REGIONAL ADULT PARENTERAL DRUG MONOGRAPH						
Southern Sud	GENERIC NAME			HIGH			
Health		rocuronium					
	CHECK						
Effective Date: Dec 2011	CLASSIFICATION	OTHER NAMES		PAGE			
Revised Date: Dec 2022	Neuromuscular blocking agent	Zemuron		1 of 2			
ADMINISTRATION POL	<u> </u>						
IV Infusion – Administration restricted to nurses experienced in ED/CARDIAC ROOM/ICU/PACU							
	administered by a nurse under		ber				
RECONSTITUTION/DILUTION/ADMINISTRATION:							
Available as: $10 \text{ mg/mL} - 3$	5 mL vial - REFRIGERATE						
IV Bolus: Undiluted over 1 to 2 minutes							
IV Infusion: Pump Library:							
Drug Library	Dose Rate	Short Name	Care Unit				
Yes	mcg/kg/min	roc300	Critical Care				
Drug	Diluent	Final Volume (VTBI)	Final Concentration				
300 mg (30 mL of 10 mg/1	mL) 100 mL NS	130 mL	2.308 mg/mL				
Clinical Advisory: High Al	lert						
Soft Low Dose Limit: 2.5 mcg/kg/min Soft High Dose Limit: 16 mcg/kg/min							
DOSAGE: IV Bolus:	0.6 to 1.2 mg/kg						
Maintenance dose:	2.5 to 16 mcg/kg/minute						
Maximum single dose:	1.2 mg/kg						
Maximum rate:	16 mcg/kg/minute						
Maximum concentration:	IV bolus/intermittent IV continuous	10 mg/mL 2.3 mg/mL					
STABILITY/COMPATIB		2.5 mg mi					
Stability of Final Admixture: 24 hours at room temperature							
Compatibility: Compatible in D5W, normal saline, combination dextrose/saline solutions							
and Lactated Ringer							

Southern Sud	REGIONAL ADULT PARENTERAL DRUG MONOGRAPH			
		GENERIC NAME FOCUTONIUM	HIGH ALERT DOUBLE CHECK	
Effective Date: Dec 2011	CLASSIFICATION	OTHED NAMES	DACE	

Revised Date: Dec 2022	Neuromuscular	Zemuron	2 of 2
	blocking agent		2 01 2

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Cardiovascular instability: Transient hypertension and hypotension, arrhythmias, tachycardia
- Neuromuscular myopathy syndrome: Potentiated by electrolyte abnormalities, hypermagnesemia, neuromuscular
- diseases, acidosis, acute intermittent porphyria, renal failure, hepatic failure

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Continuous cardiac monitoring
- Monitor vital signs
- Level of sedation. Ensure adequate sedation prior to administration of rocuronium
- Concurrent sedation and analgesia are needed
- Ventilation must be supported during neuromuscular blockade. Maintenance of adequate airway and respiratory support is critical
- No dosage adjustment in renal/hepatic dysfunction
- Onset of action: 1 to 2 minutes. Duration of action: 30 minutes
- Neostigmine must be readily available in combination with glycopyrrolate or atropine
- Elderly patients: Duration of action may be prolonged